Vatelizumab

Drug Profile

Vatelizumab

Alternative Names: CHR-1103; GBR 500; SAR 339658; TMC-2003; UNII-A4R7G50030

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Chromos Molecular Systems
  • Developer Glenmark Pharmaceuticals S.A.; Sanofi
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Cell adhesion molecule inhibitors; Immunosuppressants; Integrin alpha2beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • No development reported Cancer
  • Discontinued Chronic obstructive pulmonary disease; Multiple sclerosis; Retinal disorders; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 12 Jul 2016 Sanofi terminates a phase II/III trial in Multiple sclerosis based on the planned interim analysis (NCT02222948)
  • 01 Jan 2016 Vatelizumab is available for licensing as of 01 Jan 2016. http://www.glenmarkpharma.com/GLN_NWS/homepage.aspx?res=P_GLN
  • 31 Dec 2015 Sanofi terminates its licence to develop vatelizumab for Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top